or Try an Advanced Search...

    Technical Analysis for VIRX - Viracta Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.82 0.12% 0.00
    VIRX closed up 0.12 percent on Wednesday, May 8, 2024, on 23 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical VIRX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    NR7 Range Contraction 0.12%
    Narrow Range Bar Range Contraction 0.12%
    Earnings Movers Other 0.12%
    Wide Bands Range Expansion 0.12%
    Gapped Up Strength 0.12%
    Older End-of-Day Signals for VIRX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    Up 2% about 20 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above 10 DMA about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    VIRX Chart by TradingView
    Basic chart:

    Profile

    Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology

    Is VIRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
    Apr 23 Day One wins FDA nod for brain cancer therapy, Ojemda
    Apr 15 Viracta slides on lower response rate in trial for lymphoma treatment cohort
    Apr 15 Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
    Mar 7 Viracta Therapeutics GAAP EPS of -$0.35 misses by $0.04
    Mar 7 Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Feb 29 Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
    Feb 6 Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    Jan 5 CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
    Jan 4 Viracta Therapeutics Provides Clinical Update and Outlook for 2024
    See more VIRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.38
    52 Week Low 0.43
    Average Volume 114,448
    200-Day Moving Average 0.87
    50-Day Moving Average 0.94
    20-Day Moving Average 0.87
    10-Day Moving Average 0.82
    Average True Range 0.09
    RSI (14) 43.82
    ADX 16.39
    +DI 15.79
    -DI 20.18
    Chandelier Exit (Long, 3 ATRs) 1.05
    Chandelier Exit (Short, 3 ATRs) 0.93
    Upper Bollinger Bands 1.08
    Lower Bollinger Band 0.65
    Percent B (%b) 0.4
    BandWidth 49.78
    MACD Line -0.04
    MACD Signal Line -0.04
    MACD Histogram -0.0041
    Fundamentals Value
    Market Cap 31.71 Million
    Num Shares 38.6 Million
    EPS -1.24
    Price-to-Earnings (P/E) Ratio -0.66
    Price-to-Sales 0.00
    Price-to-Book 0.88
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.87
    Resistance 3 (R3) 0.87 0.85 0.86
    Resistance 2 (R2) 0.85 0.84 0.85 0.86
    Resistance 1 (R1) 0.84 0.83 0.85 0.84 0.85
    Pivot Point 0.82 0.82 0.83 0.82 0.82
    Support 1 (S1) 0.81 0.81 0.82 0.81 0.79
    Support 2 (S2) 0.79 0.81 0.79 0.79
    Support 3 (S3) 0.78 0.79 0.78
    Support 4 (S4) 0.78